| Budget Amount *help |
¥49,140,000 (Direct Cost: ¥37,800,000、Indirect Cost: ¥11,340,000)
Fiscal Year 2013: ¥11,440,000 (Direct Cost: ¥8,800,000、Indirect Cost: ¥2,640,000)
Fiscal Year 2012: ¥13,260,000 (Direct Cost: ¥10,200,000、Indirect Cost: ¥3,060,000)
Fiscal Year 2011: ¥24,440,000 (Direct Cost: ¥18,800,000、Indirect Cost: ¥5,640,000)
|
|---|
| Outline of Final Research Achievements |
Oncolytic viruses are characterized by self-replicating and tumor killing capacity, and have emerged as a promising treatment platform for cancer therapy. We previously carried out the screening of approximately 40 enterovirus strains and found that CVB3 possessed specific oncolytic activity against cell lines of human lung cancer, malignant pleural mesothelioma and breast cancer. In this study, two experiments were performed for the development of the novel oncolytic coxsackievirus B3 therapy. (1) To overcome CVB3-related organ toxicities, we constructed a novel recombinant CVB3-miRT by genetically incorporating two distinct normal tissue-specific miRNA target sequences into the CVB3 genome. We next constructed CVB3 inserting GM-CSF gene (CVB3-GM-CSF) to improve anti-tumor immunity. (2) For the purpose of producing CVB3 reagent under Good Manufacturing Practice (GMP), we developed mass production method using GMP grade reagents and instruments.
|
